BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

741 related articles for article (PubMed ID: 15893163)

  • 41. Evidence for executive deficits among users of MDMA (Ecstasy).
    Fisk JE; Montgomery C; Murphy P; Wareing M
    Br J Psychol; 2004 Nov; 95(Pt 4):457-66. PubMed ID: 15527532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance.
    Parrott AC; Lasky J
    Psychopharmacology (Berl); 1998 Oct; 139(3):261-8. PubMed ID: 9784083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of the acute subjective effects of MDMA/ecstasy.
    Baylen CA; Rosenberg H
    Addiction; 2006 Jul; 101(7):933-47. PubMed ID: 16771886
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Memory deficits associated with recreational use of "ecstasy" (MDMA).
    Morgan MJ
    Psychopharmacology (Berl); 1999 Jan; 141(1):30-6. PubMed ID: 9952062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research.
    Clemens KJ; McGregor IS; Hunt GE; Cornish JL
    Drug Alcohol Rev; 2007 Jan; 26(1):9-15. PubMed ID: 17364831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Syllogistic reasoning performance in MDMA (Ecstasy) users.
    Montgomery C; Fisk JE; Newcombe R; Wareing M; Murphy PN
    Exp Clin Psychopharmacol; 2005 May; 13(2):137-45. PubMed ID: 15943546
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hippocampal remodelling after MDMA neurotoxicity: a single case study.
    Nifosì F; Martinuzzi A; Toffanin T; Costanzo R; Vestri A; Battaglia M; Bertagnoni GE; Lupi A; Amistà P; Carollo C; Perini G
    World J Biol Psychiatry; 2009; 10(4 Pt 3):961-8. PubMed ID: 18609419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ecstasy (MDMA) and high prevalence psychiatric symptomatology: somatic anxiety symptoms are associated with polydrug, not ecstasy, use.
    Bedi G; Van Dam NT; Redman J
    J Psychopharmacol; 2010 Feb; 24(2):233-40. PubMed ID: 18832429
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.
    Reay JL; Hamilton C; Kennedy DO; Scholey AB
    J Psychopharmacol; 2006 May; 20(3):385-8. PubMed ID: 16574712
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [3,4-methylenedioxymethamphetamine ('ecstasy'): its long-term emotional and cognitive effects, and serotonin depletion].
    Molero-Chamizo A
    Rev Neurol; 2005 Jul 16-31; 41(2):108-14. PubMed ID: 16028190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA).
    Gouzoulis-Mayfrank E; Daumann J; Tuchtenhagen F; Pelz S; Becker S; Kunert HJ; Fimm B; Sass H
    J Neurol Neurosurg Psychiatry; 2000 Jun; 68(6):719-25. PubMed ID: 10811694
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Executive function in abstinent MDMA ('ecstasy') users.
    Zakzanis KK; Young DA
    Med Sci Monit; 2001; 7(6):1292-8. PubMed ID: 11687745
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.
    Sumnall HR; Cole JC; Jerome L
    J Psychopharmacol; 2006 Sep; 20(5):670-82. PubMed ID: 16401654
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal.
    Ramaekers JG; Kuypers KP; Samyn N
    Addiction; 2006 Nov; 101(11):1614-21. PubMed ID: 17034441
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effects of stereotype threat on cognitive function in ecstasy users.
    Cole JC; Michailidou K; Jerome L; Sumnall HR
    J Psychopharmacol; 2006 Jul; 20(4):518-25. PubMed ID: 16174670
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.
    Parrott AC
    J Psychopharmacol; 2005 Jan; 19(1):71-83. PubMed ID: 15671132
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users.
    Daumann J; Fischermann T; Heekeren K; Henke K; Thron A; Gouzoulis-Mayfrank E
    Psychopharmacology (Berl); 2005 Aug; 180(4):607-11. PubMed ID: 15372137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Depressive symptomatology in young adults with a history of MDMA use: a longitudinal analysis.
    Falck RS; Wang J; Carlson RG
    J Psychopharmacol; 2008 Jan; 22(1):47-54. PubMed ID: 18187532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users.
    Soar K; Parrott A; Turner J
    J Psychopharmacol; 2009 Sep; 23(7):745-58. PubMed ID: 18635698
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study.
    Schilt T; de Win MM; Koeter M; Jager G; Korf DJ; van den Brink W; Schmand B
    Arch Gen Psychiatry; 2007 Jun; 64(6):728-36. PubMed ID: 17548754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.